Jefferies Cuts Numbers on ViroPharma (VPHM) But Says Buy on "Overreaction"
Tweet
Share
E-mailGet Alerts VPHM Hot Sheet
Price: $49.96 --0%
Rating Summary:
5 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 17 | New: 5
Rating Summary:
5 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 17 | New: 5
Join SI Premium – FREE
Jefferies cut estimates and its price target on ViroPharma (NASDAQ: VPHM) from $37 to $33 but is keeping its Buy rating after the FDA approved three generic versions of Vancocin and responded to VPHM’s citizen petition, detailing their denial of 3-year exclusivity for Vancocin.
"We would be buyers on today's overreaction, as Cinryze is the critical driver of the VPHM story," the analyst said.
For an analyst ratings summary and ratings history on ViroPharma click here. For more ratings news on ViroPharma click here.
Shares of ViroPharma closed at $22.44 yesterday.
"We would be buyers on today's overreaction, as Cinryze is the critical driver of the VPHM story," the analyst said.
For an analyst ratings summary and ratings history on ViroPharma click here. For more ratings news on ViroPharma click here.
Shares of ViroPharma closed at $22.44 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AppFolio (APPF) PT Raised to $275 at KeyBanc
- DA Davidson Starts Napco Security Technologies, Inc. (NSSC) at Buy
- Stifel Downgrades Caterpillar (CAT) to Hold
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
